Elan Pharmaceuticals

Elan Pharmaceuticals
Share

Elan Pharmaceuticals

 •  August 23, 2016

DUBLIN, Aug. 23, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is indicated for the treatment of cleansing of the colon...

Elan Pharmaceuticals

 •  June 16, 2016

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' Ofirmev® (acetaminophen) injection 1000 mg/100 mL.
As previously announced, Perrigo can launch a generic version of Ofirmev® (acetaminophen) injection on December...

Elan Pharmaceuticals

 •  May 18, 2016

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the UBS Global Healthcare Conference at 1:30 PM EDT on Tuesday, May 24, 2016 at the Grand Hyatt in New York City, NY. Interested parties can access the presentation webcast at...

Elan Pharmaceuticals

 •  May 3, 2016

Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets, the first OTC store brand equivalent to Mucinex® 1200mg DM extended-release tablets, being introduced to retail and wholesale customers. First shipments of this new...

Elan Pharmaceuticals

 •  May 2, 2016

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Valeant Pharmaceutical International, Inc.'s BenzaClin® Pump Topical Gel. Shipments to customers have already commenced.
BenzaClin® Pump Topical Gel (clindamycin phosphate 1% and benzoyl...

Elan Pharmaceuticals

 •  April 28, 2016

Announces Resignation of Marc Coucke as Executive Vice President and General Manager Branded Consumer Healthcare
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced that Mr. Sharon Kochan, Perrigo's Executive Vice President and General Manager,...

Elan Pharmaceuticals

 •  April 22, 2016

Perrigo Company plc (NYSE: PRGO; TASE) today released the following statement regarding recent media coverage concerning Chairman and CEO Joseph C. Papa:
"We are aware of the speculation regarding our Chairman and CEO Joseph Papa. As is our company policy, we do not comment on speculation or market rumor."
About Perrigo
Perrigo Company plc, a top...

Elan Pharmaceuticals

 •  April 12, 2016

Perrigo Company plc (NYSE: PRGO; TASE) today announced the first-to-market launch of the over-the-counter (OTC) store brand equivalent to Glucerna® aseptic adult nutritional shake for people with diabetes. First shipments of this new store brand aseptic shake have already been initiated. This product is packaged and marketed as a store brand or...

Elan Pharmaceuticals

 •  March 23, 2016

DUBLIN, March 23, 2016 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg extended-release tablets, the OTC store brand equivalent to Mucinex® 1200mg extended-release tablets to retail and wholesale customers. First shipments of this new store branded product...

Elan Pharmaceuticals

 •  March 16, 2016

Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), showcased eight new product SKUs at the 2016 Global Pet Expo: SENTRY® Vantaguard™ 2 and SENTRY® Flea & Tick Collar for Dogs.
SENTRY Vantaguard 2 Flea Treatment
SENTRY Vantaguard 2 contains the same active ingredients as Advantage® II, imidacloprid and pyriproxyfen, but...